Regeneron Pharmaceuticals reported $15.5B of revenue over the trailing twelve months, +9.3% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $15.5B (to Q2 2026). Net income: $4.33B, trailing twelve months to Q2 2026. Free cash flow: $3.76B, trailing twelve months to Q2 2026. Operating margin: 24%, trailing twelve months to Q2 2026.

REGNRegeneron Pharmaceuticals

Healthcare

$746.46+25% 1Y

$746.46

$553.3252 weeks$852.16

REGN as reported

Regeneron Pharmaceuticals reported $15.5B of revenue over the trailing twelve months, +9.3% on the year before. 11 reported series are charted on this page, each one as filed.

$15.5B

Revenue, trailing twelve months · to Q2 2026 · +9.3% against the twelve months before

Net income: $4.33B
Net income · −2.9% year on year · trailing twelve months to Q2 2026
Free cash flow: $3.76B
Free cash flow · −2.4% year on year · trailing twelve months to Q2 2026
Operating margin: 24%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for REGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$15.5B	+9.3%	Q2 2026
Net income	$4.33B	−2.9%	Q2 2026
EPS	$40.47	+1.9%	Q2 2026
Gross margin	97%	n/a	Q1 2018 · 33 quarters behind
Operating margin	24%	n/a	Q2 2026
Net margin	28%	n/a	Q2 2026
ROE	14%	n/a	Q2 2026
ROA	11%	n/a	Q2 2026
ROIC	12%	n/a	Q2 2026
Free cash flow	$3.76B	−2.4%	Q2 2026
P/E	18.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.